|
PBT-1033
|
DB05565 |
|
|
(Hydroxyethyloxy)Tri(Ethyloxy)Octane
|
DB04233 |
|
|
1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
|
DB06896 |
|
|
N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide
|
DB04234 |
|
|
P-Hydroxybenzoic Acid
|
DB04242 |
|
|
5-Methyluridine 5'-Monophosphate
|
DB04243 |
|
|
(1S)-1-C-{(2R)-6-[(2R)-2-Butanyl]-5,10-dihydroxy-4-oxo-1,2,3,4-tetrahydro-2-anthracenyl}-5-deoxy-1-O-methyl-D-xylulose
|
DB04240 |
|
|
N-Pyridoxyl-2-Methylalanine-5-Phosphate
|
DB04241 |
|
|
beta-(1->4)-galactotriose
|
DB04248 |
|
|
Zinc Substituted Heme C
|
DB04249 |
|
|
Ramucirumab
|
DB05578 |
[Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.] |
|
CRA_23653
|
DB04246 |
|
|
(2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide
|
DB04244 |
|
|
Motesanib
|
DB05575 |
|
|
Brivaracetam
|
DB05541 |
[Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].] |
|
1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE
|
DB06872 |
|
|
3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide
|
DB04210 |
|
|
17-METHYL-17-ALPHA-DIHYDROEQUILENIN
|
DB06871 |
|
|
Alanosine
|
DB05540 |
[An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.] |
|
17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
|
DB06870 |
|
